{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT07150806","nct_id":"NCT07150806","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct07150806. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive RYZ101 IV and amino acids, with L-arginine and L-lysine, IV on day 1 of each cycle. Cycles repeat every 8 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients receive gallium Ga 68-DOTATATE IV and undergo PET scan or SSTR PET scan, CT scan, MRI and undergo blood and urine sample collection and may undergo echocardiography or MUGA scan throughout the study.","label":"Treatment (RYZ101)","type":"EXPERIMENTAL"}],"collaborators":["RayzeBio, Inc."],"completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"conditions":["Recurrent Meningioma"],"enrollment":{"count":30,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Actinium Ac 225 DOTATATE RYZ101","otherNames":["225Ac-DOTA-TATE RYZ101","225Ac-Oxodotreotide","Actinium Ac 225-Dotatate RYZ101","ACTINIUM AC-225 DOTATATE","RYZ 101","RYZ-101","RYZ101"],"type":"DRUG"},{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Specimen Collection"],"type":"PROCEDURE"},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","tomography"],"type":"PROCEDURE"},{"name":"Echocardiography Test","otherNames":["EC","Echocardiography"],"type":"PROCEDURE"},{"name":"Gallium Ga 68-DOTATATE","otherNames":["(68)Ga-DOTA-TATE","68Ga-DOTA-0-Tyr3-Octreotate","68Ga-DOTATATE","Gallium Ga 68 Oxodotreotide","Gallium Oxodotreotide Ga-68","Gallium-68 DOTA-DPhe1, Tyr3-octreotate"],"type":"RADIATION"},{"name":"L-lysine/L-arginine-containing Amino Acid","otherNames":["Amino Acid Renal Protectant Solution","Amino Acid Solution-containing L-lysine and L-arginine","Intravenous L-lysine/L-arginine-containing Amino Acid Solution","L-lysine/L-arginine AA Solution","Lysine-Arginine Amino Acid Solution","Lysine/Arginine Amino Acid Solution","Radioprotective Amino Acid Solution"],"type":"DRUG"},{"name":"Magnetic Resonance Imaging","otherNames":["Magnetic Resonance","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI"],"type":"PROCEDURE"},{"name":"Multigated Acquisition Scan","otherNames":["Blood Pool Scan","Equilibrium Radionuclide Angiography","Gated Blood Pool Imaging","Gated Heart Pool Scan","MUGA","MUGA Scan","Multi-Gated Acquisition Scan","Radionuclide Ventriculogram Scan","Radionuclide Ventriculography","RNV Scan","RNVG","SYMA Scanning","Synchronized Multigated Acquisition Scanning"],"type":"PROCEDURE"},{"name":"Positron Emission Tomography","otherNames":["Medical Imaging, Positron Emission Tomography","PET","PET Scan","Positron emission tomography (procedure)","Positron Emission Tomography Scan","Positron-Emission Tomography","PT"],"type":"PROCEDURE"},{"name":"Somatostatin Receptor Positron Emission Tomography","otherNames":["SSTR-PET"],"type":"PROCEDURE"}],"last_update":"2026-08-13","lead_sponsor":"Joshua Palmer","official_title":"Progressive/Recurrent Intracranial Meningioma Treated With SSTR-Targeted Alpha Emitter RYZ101 (PRIMe-STAR)","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival (PFS)","timeFrame":"At 6 months"}],"references":[],"start_date":{"date":"2025-11-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma","url":"https://clinicaltrials.gov/study/NCT07150806"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct07150806"}